Modality
small molecule (topical)
Mechanism
JAK1/JAK2 inhibitor
Targets
JAK1, JAK2
Storage
room temperature
Approved
atopic dermatitis — FDA 2021 · vitiligo — FDA 2022
In trial
lichen planus, HS
Black-box warnings
serious infections; mortality; malignancy; MACE; thrombosis
Monitoring
max 20% BSA / 60 g per week
Sources
Last verified
2026-04-14
lib/moa-data.ts for the shape; add an entry keyed by ruxolitinib (topical).